73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ascendis Pharma A-S ADR
Open
SectorHealthcare
215.35 0.81
Overview
Share price change
24h
Min
212.31
Max
218.37
Income | -22M -61M |
|---|---|
Sales | 56M 214M |
Profit margin | -28.549 |
Employees | 1,017 |
EBITDA | -56M -53M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +24.58% upside |
Next Earnings | 11 Feb 2026 |
|---|
Market Cap | 886M 13B |
|---|---|
Previous open | 214.54 |
Previous close | 215.35 |
News Sentiment
By Acuity
50%
50%
151 / 361 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Ascendis Pharma A-S ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ascendis Pharma A-S ADR Forecast
Price Target
By TipRanks
24.58% upside
12 Months Forecast
Average 267.92 USD 24.58%
High 325 USD
Low 240 USD
Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.
Sentiment
By Acuity
151 / 361 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ascendis Pharma A-S ADR
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Live chat